首页> 外文期刊>Nature reviews. Gastroenterology & hepatology >Pancreatic cancer: understanding and overcoming chemoresistance.
【24h】

Pancreatic cancer: understanding and overcoming chemoresistance.

机译:胰腺癌:了解和克服化学耐药性。

获取原文
获取原文并翻译 | 示例
           

摘要

Pancreatic cancer is a highly aggressive malignancy. This feature is believed to be partly attributable to the chemotherapy-resistant characteristics of specific subgroups of pancreatic cancer cells, namely those with an epithelial-mesenchymal transition (EMT) phenotype and cancer stem cells. Accumulating evidence suggests that several new and emerging concepts might be important in the drug-resistant phenotype of these cell types. An understanding of the molecular mechanisms underlying drug resistance in patients with pancreatic cancer might help researchers to devise novel strategies to overcome such resistance. In particular, microRNAs (miRNAs) seem to be critical regulators of drug resistance in pancreatic cancer cells. Selective and targeted elimination of cells with an EMT phenotype and cancer stem cells could be achieved by regulating the expression of specific miRNAs.
机译:胰腺癌是一种高度侵袭性的恶性肿瘤。据信该特征部分归因于胰腺癌细胞的特定亚群的化学疗法抗性特征,即具有上皮-间质转化(EMT)表型和癌症干细胞的那些。越来越多的证据表明,一些新出现的概念可能对这些细胞类型的耐药表型很重要。对胰腺癌患者抗药性的分子机制的了解可能有助于研究人员设计新的策略来克服这种抗药性。特别是,microRNA(miRNA)似乎是胰腺癌细胞耐药性的关键调节剂。可以通过调节特定miRNA的表达来选择性和靶向消除具有EMT表型的细胞和癌症干细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号